Replies to post #408715 on Amarin Corp Plc (AMRN)

[Whalatane]

Zip. with the generics fully entrenched in the US ...this market is a lose / lose for AMRN.
They have been lowering their prices to their major buyers to maintain market share ...and trying to at least breakeven.
If they spend significant $ on marketing they will start losing money and drive at least half of the new scripts to the generics.
Thats why they are focused on the EU where they still retain market exclusivity

Kiwi